ReviewThe Yale journal of biology and medicine2015
Approaches to identifying synthetic lethal interactions in cancer.
Review in The Yale journal of biology and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Article
- Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.Experimental hematology & oncology · 2023Article
- Synthetic lethality prediction in DNA damage repair, chromatin remodeling and the cell cycle using multi-omics data from cell lines and patients.Scientific reports · 2023Article
- Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic targets.Oncogene · 2021Article
- Harnessing the Co-vulnerabilities of Amino Acid-Restricted Cancers.Cell metabolism · 2021Review
- A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities.Nature communications · 2020Article
- Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells.Molecular therapy. Nucleic acids · 2019Article
- Article
- Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.Molecules (Basel, Switzerland) · 2018Review
- Synthetic Lethal Networks for Precision Oncology: Promises and Pitfalls.Journal of molecular biology · 2018Review
- A Plasmodium Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice.Infection and immunity · 2018Article
- Improved detection of synthetic lethal interactions inProceedings of the National Academy of Sciences of the United States of America · 2017Article
- The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.Oncology research · 2017Article
- Transcriptional reprogramming in cellular quiescence.RNA biology · 2017Review
- Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.Oncogene · 2017Article
- Loss-of-function genetic tools for animal models: cross-species and cross-platform differences.Nature reviews. Genetics · 2017Review
- TP53 mutations in epithelial ovarian cancer.Translational cancer research · 2016Article
- Chemo-Genetic Interactions Between Histone Modification and the Antiproliferation Drug AICAR Are Conserved in Yeast and Humans.Genetics · 2016Article
- Ubc13: the Lys63 ubiquitin chain building machine.Oncotarget · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Targeting synthetic lethal interactions is a promising new therapeutic approach to exploit specific changes that occur within cancer cells. Multiple approaches to investigate these interactions have been developed and successfully implemented, including chemical, siRNA, shRNA, and CRISPR library screens. Genome-wide computational approaches, such as DAISY, also have been successful in predicting synthetic lethal interactions from both cancer cell lines and patient samples. Each approach has its advantages and disadvantages that need to be considered depending on the cancer type and its molecular alterations. This review discusses these approaches and examines case studies that highlight their use.
Indexed as
Identifiers
26029013PMC4445436What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.